Login to Your Account



Elan, Cambridge in $10M Protein Misfolding Drug Discovery Pact

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, November 30, 2011
Elan Corp. plc is entering a $10 million alliance with the University of Cambridge that will focus on the discovery of drugs that modulate protein misfolding processes associated with neurodegenerative conditions, such as Alzheimer's disease and Parkinson's disease.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription